A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Jan 2024 Results of post hoc analysis examining Clinical Characteristics in Chinese Patients with Schizophrenia, published in the CNS Drugs
05 Oct 2021 Results evaluating efficacy and safety of the newly developed paliperidone palmitate 6-month (PP6M) LAI relative to the paliperidone palmitate 3-month (PP3M) LAI in patients with schizophrenia presented at the 34th Annual Congress of the European College of Neuropsychopharmacology
25 Sep 2020 Results presented in a Janssen Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com